[go: up one dir, main page]

HK1058146A1 - Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders - Google Patents

Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Info

Publication number
HK1058146A1
HK1058146A1 HK04100882A HK04100882A HK1058146A1 HK 1058146 A1 HK1058146 A1 HK 1058146A1 HK 04100882 A HK04100882 A HK 04100882A HK 04100882 A HK04100882 A HK 04100882A HK 1058146 A1 HK1058146 A1 HK 1058146A1
Authority
HK
Hong Kong
Prior art keywords
neuropathic pain
formulations
compositions
pain disorders
inhibiting progression
Prior art date
Application number
HK04100882A
Other languages
English (en)
Inventor
Ramasharma Kristipati
Peter Isadore Adriaenssens
Stephen Scott Bowersox
Theresa Gadbois
Robert R Luther
Gary Arthur Amstutz
Mark Raymond Pettus
Kishochandra Gohil
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of HK1058146A1 publication Critical patent/HK1058146A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
HK04100882A 1995-06-27 2004-02-10 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders HK1058146A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (1)

Publication Number Publication Date
HK1058146A1 true HK1058146A1 (en) 2004-05-07

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100882A HK1058146A1 (en) 1995-06-27 2004-02-10 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Country Status (14)

Country Link
EP (2) EP0835126B1 (xx)
JP (1) JP2838073B2 (xx)
AT (2) ATE235914T1 (xx)
AU (1) AU695166B2 (xx)
CA (1) CA2224795C (xx)
DE (3) DE69637021T2 (xx)
DK (2) DK1336409T3 (xx)
ES (2) ES2194998T3 (xx)
FR (1) FR05C0027I2 (xx)
HK (1) HK1058146A1 (xx)
LU (1) LU91181I2 (xx)
NL (1) NL300201I2 (xx)
PT (2) PT1336409E (xx)
WO (1) WO1997001351A1 (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2319038A1 (en) * 1998-02-20 1999-08-26 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
WO2004050688A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)
CA2508129C (en) 2002-12-02 2012-06-26 Xenome Ltd Novel x-conotoxin peptides (-i)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE365174T1 (de) 2003-01-28 2007-07-15 Microbia Inc Zusammensetzungen zur behandlung von gastrointestinalen störungen
EP1689401A1 (en) 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Method for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
CN101557820A (zh) * 2006-11-04 2009-10-14 安奈根株式会社 ω芋螺毒素
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
ES2608050T3 (es) 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
KR101683318B1 (ko) 2008-12-31 2016-12-07 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RU2675364C2 (ru) 2013-04-12 2018-12-19 Арделикс, Инк Nhe3-связывающие соединения и способы ингибирования транспорта фосфатов
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
CN118221656A (zh) 2017-01-09 2024-06-21 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
ATE165977T1 (de) * 1991-12-30 1998-05-15 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
DE122005000043I1 (de) 2006-06-29
FR05C0027I1 (xx) 2005-08-12
JPH09104634A (ja) 1997-04-22
WO1997001351A1 (en) 1997-01-16
DK0835126T3 (da) 2003-07-14
FR05C0027I2 (xx) 2006-12-29
EP1336409A1 (en) 2003-08-20
DE69637021T2 (de) 2008-01-10
NL300201I2 (nl) 2006-02-01
ATE235914T1 (de) 2003-04-15
DE122005000043I2 (de) 2006-08-03
DE69637021D1 (de) 2007-05-24
DK1336409T3 (da) 2007-08-13
EP0835126B1 (en) 2003-04-02
EP1336409B1 (en) 2007-04-11
PT1336409E (pt) 2007-06-29
NL300201I1 (nl) 2005-09-01
ES2194998T3 (es) 2003-12-01
AU695166B2 (en) 1998-08-06
CA2224795C (en) 2001-04-03
ATE359086T1 (de) 2007-05-15
PT835126E (pt) 2003-07-31
DE69627153T2 (de) 2003-12-04
ES2283671T3 (es) 2007-11-01
DE69627153D1 (de) 2003-05-08
JP2838073B2 (ja) 1998-12-16
AU6400296A (en) 1997-01-30
CA2224795A1 (en) 1997-01-16
LU91181I2 (fr) 2005-09-06
EP0835126A1 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
HK1058146A1 (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
IL121170A0 (en) Compositions for the treatment of dermatological disorders
BG101901A (en) 2-methyl-thieno-benzodiazepine formulation for oral application
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
EP0788359A4 (en) AGENTS FOR THE PRODUCTION OF MEDICINES FOR TREATING VARIOUS REFRACTORY DISORDER
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
AU7397094A (en) Prevention and treatment of alzheimer's disease
HUP9601635A2 (en) Oral formulations of s(+)-etodolac
AU6328696A (en) Treatment of hemoglobinopathies
CA2279498A1 (en) The use of levobupivacaine in paediatric surgery
HK1029937A1 (en) Use of phanquinone for the treatment of alzheimer s disease.
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
GB9303157D0 (en) Treatment of a group of related disorders
GB9419048D0 (en) Treatment of muscular disorders
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
AU1807592A (en) New combination preparation for treatment of parkinson's disease
ZA947912B (en) Treatment of medical disorders associated with free radical formation
CA2221592A1 (en) Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction
GR3034688T3 (en) Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions
AU124671S (en) Elongate frame extension
IL106917A0 (en) Compositions for the treatment of skin disorders
AU7340894A (en) Treatment of oral ailments
BG99596A (en) Preparation for the treatment of gums and teeth
GB9400970D0 (en) Manufacture of an oral solid dose form of lactitol

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130626